Clinical Effect Analysis Of The Neoadjuvant Chemotherapy On Advanced Ovarian Carcinoma

ObjectiveThis study was aimed at evaluate the effects of neoadjuvant chemotherapy in adavanced ovarian carcinoma.MethodsRetrospective analysis of 163 patients with advanced ovarian carcinoma treated between 1996 and 2007 was performed.Patients were divided into two groups. In the period 1996-2001, all patients underwent primary debulking surgery were defined as control group (A group). In the period 2002-2007, patients surgically evaluated to receive primary chemotherapy (B1 group) or primary debulking surgery (B2 group) were defined as research group (B group).ResultsThe optimal operation rate of the B group was significantly higher than that of the A group (74% vs 44%, P＜0.05). The optimal operation rate of the B1 group was the same to the B2 group (71% vs 75%, P＞0.05).The 3-year survival rate of the B group was significantly higher than that of the A group (43% vs 25%, P＜0.05). The 3-year survival rate of the B1 group was the same to the B2 group (39% vs 47%, P＞0.05).ConclusionHigher optimal operation rate and longer 3-year survival rate can be achieved in patients with advanced ovarian carcinoma by the use of neoadjuvant chemotherapy.